A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam

Documenti analoghi

• Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants
  di: Xue‐Qing Li, et al.
  Pubblicazione: (2024)
• The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
  di: Chandrali S. Bhattacharya, et al.
  Pubblicazione: (2024)
• Using pharmacokinetic tomography—Cutaneous pharmacokinetics of topical drugs (FDA)
  Pubblicazione: (2024)
• A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions
  di: Christina Kovar, et al.
  Pubblicazione: (2024)
• Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach
  di: Michael J. Hanley, et al.
  Pubblicazione: (2024)